Oncolytics Biotech Plans Move from Alberta to Nevada
Oncolytics Biotech Inc., a clinical-stage immunotherapy company, plans to move its jurisdiction from Alberta, Canada to Nevada, USA. A special shareholder meeting to vote on this reorganization was postponed due to U.S. SEC delays caused by a federal government shutdown. The meeting will be rescheduled soon. This information was originally published by Oncolytics Biotech via Business Wire.
Oncolytics Biotech Inc., a clinical-stage immunotherapy company developing pelareorep, has announced plans for a corporate reorganization involving a change of jurisdiction from Alberta, Canada to the State of Nevada, USA. The company was set to hold a special meeting of shareholders to vote on this and other related transactions but has postponed the meeting due to delays at the U.S. Securities and Exchange Commission caused by a recent federal government shutdown. Oncolytics intends to reschedule the meeting as soon as practicable. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251120748929) on November 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
